3-三氟甲基苯胺 | 26130-45-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-三氟甲基苯胺
• 中文别名: 3-三氟甲基-苯甲脒
• 英文名称: 3-(trifluoromethyl)benzamidine
• 英文别名: 3-TrifluoroMethyl-Benzamidine；3-(trifluoromethyl)benzenecarboximidamide
• CAS: 26130-45-0
• 化学式: C₈H₇F₃N₂
• mdl: MFCD05663379
• 分子量: 188.152
• InChiKey: QDVHJZUOARUZME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  49.9
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2925290090

反应信息

• 作为反应物：
  描述：

  3-三氟甲基苯胺 以27%的产率得到
  参考文献：
  名称：

  JUBY P. F.; HUDYMA T. W.; BROWN M.; ESSERY J. M.; PARTYKA R. A., J. MED. CHEM., 1979, 22, NO 3, 263-269

  摘要：

  DOI：
• 作为产物：
  描述：

  间三氟甲基苯腈 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 以100%的产率得到3-三氟甲基苯胺
  参考文献：
  名称：

  Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model

  摘要：

  Neuropathic pain is a chronic pain caused by a lesion or disease affecting the somatosensory nervous system. To date, no specific treatment has been developed to cure this pain. Antidepressants and anticonvulsant drugs are used, but they do not demonstrate universal efficacy, and they often cause detrimental adverse effects. Some studies highlighted the efficacy of sildenafil, a well-known inhibitor of phosphodiesterase 5 (PDE5, (IC50=3.3 nM)), in models of pain. Based on these results, we focused our attention on MY 5445, another known PDE5 inhibitor. Homologues, isosteres and structural analogues of MY 5445 were designed and all synthesized compounds were evaluated for their inhibitory activity toward PDE5. Selectivity profiles towards other PDE1-4 isoenzymes, water solubility and stability in acidic medium of the most potent PDE5 inhibitors were determined and the aminophthalazine 16h and its mimetic 41n (3-aminoindazole) were evaluated in comparison to MY 5445 (4b) in vivo in a model of neuropathic pain induced by sciatic nerve cuffing in mice (3 and 0.5 mg/kg, ip twice a day). Both compounds showed the same efficacy on neuropathic allodynia as MY 5445, and thus produced a significant relief of mechanical hypersensitivity after 12 days of treatment. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.05.026

文献信息

• [EN] PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'ACIDE PHOSPHONIQUE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2Y12
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009069100A1

  公开（公告）日：2009-06-04

  The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I).

  这项发明涉及含有膦酸基团的2-苯基嘧啶衍生物，以及它们作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏-、肝脏和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的疾病或状况中的使用，包括人类和其他哺乳动物中的血栓形成。（I）。
• [EN] BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE À UTILISER EN TANT QU'INHIBITEURS SÉLECTIFS DE PROTÉINE KINASE
  申请人：AB SCIENCE

  公开号：WO2014202763A1

  公开（公告）日：2014-12-24

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof. Wherein n, R1, R2, R3, R4, R5, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.

  本发明涉及式(I)的化合物或其药用可接受的盐。其中n、R1、R2、R3、R4、R5、A、Q和X如描述中所定义。这些化合物选择性地调节、调控和/或抑制信号传导，该信号传导由涉及多种人类和动物疾病的某些天然和/或突变的蛋白激酶介导，如细胞增殖、代谢、过敏和退行性疾病。更具体地说，这些化合物是有效且选择性的天然和/或突变的c-kit抑制剂。
• 一种新型电子传输材料
  申请人：烟台盛华液晶材料有限公司

  公开号：CN111747900B

  公开（公告）日：2023-06-27

  本发明公开了一种新型电子传输材料，该材料是具有通式（Ⅰ）的有机化合物，，该材料作为电子传输材料具有良好的电子接受能力和电子传输能力；由于三氟甲基中的氟原子阻挡了外界氧气和水的进攻，有效阻止了分子陷阱的形成，具有较好的化学和物理稳定性，本发明材料可应用于有机光电导体（OPCS）、有机电致发光二极管（OLED）、有机太阳能电池（OPVCS）、有机场效应晶体管（OFETS）、光电探测以及传感器等诸多领域。
• SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS
  申请人：NORTHWESTERN UNIVERSITY

  公开号：US20200392116A1

  公开（公告）日：2020-12-17

  Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.

  本文披露了包括取代吡唑、取代嘧啶和取代三唑在内的取代杂环化合物。本文披露的取代杂环化合物被证明在抑制c-MYC方面具有用途，并可用作治疗癌症和细胞增殖性疾病的治疗药物。
• Pyridine and pyrimidine derivatives
  申请人：——

  公开号：US20030216382A1

  公开（公告）日：2003-11-20

  The present invention provides compounds of formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 and X are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明提供了化合物的公式（I）1，其中R1、R2、R3、R4和X如规范中所定义，以及其药用盐。这些化合物可用于治疗和/或预防与DPP IV相关的疾病，如糖尿病，特别是非胰岛素依赖型糖尿病和糖耐量受损。